ArieSBelldegrunMD
Urology • Los Angeles, CAChief of the Division of Urologic Oncology and Director of Urologic Research in the Department of Urology at the University of California, Los Angeles. He is a UCLA Professor of Urology, Clinical Director of the UCLA Prostate Disease Research Program and Surgical Director of the UCLA Kidney Cancer Program. He is also the Founder and Chairman of the Board of Agensys, Inc
Dr. Belldegrun is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
200 Medical Plz
Los Angeles, CA 90095Phone+1 310-794-7700Fax+1 310-301-8751- Is this information wrong?
Education & Training
Clinical Center at the National Institutes of HealthResidency, Urology, 1987 - 1988- Clinical Center at the National Institutes of HealthResidency, Surgery, 1985 - 1987
Brigham and Women's Hospital/Harvard Medical SchoolResidency, Urology, 1982 - 1985
The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1975
Certifications & Licensure
CA State Medical License 1988 - 2025
NY State Medical License 1987 - 2024
MA State Medical License 1983 - 2003
VA State Medical License 1985 - 2000
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2009-2014
- Top Doctors:LA Area Castle Connolly, 2013
- America's Top Doctors for Cancer Castle Connolly, 2005-2013
- Join now to see all
Clinical Trials
- Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer Start of enrollment: 1999 Jun 01
- Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer Start of enrollment: 2000 Apr 01
- Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer Start of enrollment: 2000 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell Carcinoma.Cedric Lebacle, Aydin Pooli, Brian Shuch, Nagesh Rao, Karim Chamie, Nils Kroeger, Izak Faiena, Sandy Liu, Erika L Wood, Arie Belldegrun, Alexandra Drakaki, Allan J Pan...> ;Cancer Investigation. 2024 Jan 1
- 9 citationsA Phase I, Open-label, Dose-escalation, and Cohort Expansion Study to Evaluate the Safety and Immune Response to Autologous Dendritic Cells Transduced With AdGMCA9 (DC...Izak Faiena, Begoña Comin-Anduix, Beata Berent-Maoz, Adrian Bot, Nazy Zomorodian, Ankush Sachdeva, Jonathan W. Said, Gardenia Cheung-Lau, Jia Pang, Mignonette H. Macab...> ;Journal of Immunotherapy. 2020 Nov 1
- 4 citationsEvaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patientsJohannes Heide, Silvia Ribback, Tobias Klatte, Shahrokh F. Shariat, Martin Burchardt, Frank Dombrowski, Arie S. Belldegrun, Alexandra Drakaki, Allan J. Pantuck, Nils K...> ;World Journal of Urology. 2020 Jun 1
- Join now to see all
Press Mentions
Local Companies and Research Institutes at Forefront of Cancer Immunotherapy DevelopmentMarch 13th, 2023- AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell TherapyNovember 29th, 2022
- Ginkgo Bioworks to Go Public with over $1.6 Billion in ProceedsSeptember 14th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
